Product image of Menjugate (N. Meningitidis Group C (Strain C11) Oligosaccharide Conjugated To Corynebacterium Diphtheriae Crm19) supplied by GNH India

Menjugate

Active Ingredient:
N. Meningitidis Group C (Strain C11) Oligosaccharide Conjugated To Corynebacterium Diphtheriae Crm19
Origin:
EU

Menjugate (N. Meningitidis Group C (Strain C11) Oligosaccharide Conjugated To Corynebacterium Diphtheriae Crm19)

N. Meningitidis Group C (Strain C11) Oligosaccharide Conjugated To Corynebacterium Diphtheriae Crm19, the active ingredient in Menjugate, is a vaccine presented as an injectable solution for intramuscular use. It induces immunity to prevent invasive disease caused by Neisseria meningitidis serogroup C, primarily in children, adolescents and at‑risk adults.

GNH India supplies Menjugate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution aligned to EU regulatory standards.

Manufacturer / TM Owner

Gsk Vaccines S.R.L.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Menjugate is a conjugate vaccine that targets Neisseria meningitidis serogroup C and is used to prevent invasive meningococcal disease.

  • Infants and toddlers: induces protective antibodies to prevent serogroup C meningococcal disease in early childhood.
  • Adolescents and young adults: boosts immunity to maintain protection during high‑risk age periods.
  • Adults at increased risk (e.g., complement deficiency, travel to endemic areas): provides targeted protection against serogroup C infection.

How It Works

  • The conjugate vaccine links the polysaccharide capsule of Neisseria meningitidis group C to the diphtheria toxoid carrier protein CRM197. This conjugation enables T‑cell dependent activation, leading to robust B‑cell antibody production and immunological memory, thereby providing long‑lasting protection against serogroup C infection.

Side Effects

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the injection site.
  • Redness or swelling: localized erythema or edema.
  • Fever: transient low‑grade temperature rise.
  • Headache or fatigue: mild systemic symptoms.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical attention.
  • Guillain‑Barré syndrome: rare neurologic disorder with progressive weakness.
  • Seizures: infrequent occurrence, especially in febrile children.
  • Severe hypotension: marked drop in blood pressure post‑vaccination.
  • Acute allergic reaction: including angioedema or bronchospasm.

Precautions & Warnings

Before administration, consider the following precautions:

  • Allergy assessment: avoid in individuals with severe hypersensitivity to any vaccine component.
  • Pregnancy: use only if the potential benefits outweigh uncertain risks; data are limited.
  • Immunocompromised patients: vaccine may be less effective; evaluate need on a case‑by‑case basis.
  • Concurrent vaccines: may be given at separate sites; monitor for additive reactogenicity.
  • Age restrictions: not approved for use in children under two months of age.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Vaccination may be influenced by other agents.

Major Interactions (Avoid)

  • Live bacterial or viral vaccines: concurrent administration may interfere with immune response.
  • Immunoglobulin or blood products within 4 weeks: can diminish antibody formation.
  • Therapeutic monoclonal antibodies targeting B cells: may reduce vaccine efficacy.

Moderate Interactions (Monitor Closely)

  • Corticosteroids or other immunosuppressants: may lower immunogenicity; consider timing of doses.
  • Prophylactic antipyretics: could blunt antibody response, use only if needed for symptom control.
  • Co‑administration with other conjugate vaccines: monitor for additive reactogenicity.

Frequently Asked Questions

Menjugate is a conjugate vaccine indicated to prevent invasive disease caused by Neisseria meningitidis serogroup C. It is administered to individuals at risk of meningococcal infection, including infants, adolescents, and adults with specific risk factors.

The active ingredient links the group C polysaccharide to the diphtheria toxoid CRM197, creating a conjugate that stimulates a T‑cell dependent immune response. This results in robust antibody production and immunological memory against serogroup C meningococcus.

The dosing schedule for Menjugate is determined by the prescribing clinician based on age, risk factors, and local immunization guidelines. Typically, a primary series followed by a booster is recommended, but exact timing and number of doses are individualized.

Safety data for Menjugate in pregnancy are limited. It may be administered if the potential benefit to the mother outweighs any unknown risk to the fetus. Breastfeeding is not a contraindication, but mothers should discuss vaccination with their healthcare provider.

To order Menjugate, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping options and necessary import documentation.

Menjugate is a serogroup C conjugate vaccine, whereas some alternatives combine multiple serogroups (A, C, W, Y) or use different carrier proteins. Conjugate vaccines like Menjugate generally produce stronger, longer‑lasting immunity in younger children compared with polysaccharide‑only formulations.

Menjugate must be stored refrigerated at 2‑8 °C. Keep the vials in the original packaging, protect them from light, and avoid freezing or shaking. If temperature excursions occur, discard the product according to local regulations.

Menjugate is given as an intramuscular injection, usually into the deltoid muscle of the upper arm or the anterolateral thigh in younger children. The injection should be performed by a qualified healthcare professional using aseptic technique.

The most serious adverse events reported with Menjugate include severe allergic reactions such as anaphylaxis, Guillain‑Barré syndrome, and seizures. Any signs of a severe reaction require immediate medical evaluation and treatment.

Menjugate is contraindicated in individuals with a known severe hypersensitivity to any component of the vaccine, including the diphtheria toxoid carrier. It is also not recommended for infants younger than two months of age.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing N. Meningitidis Group C (Strain C11) Oligosaccharide Conjugated To Corynebacterium Diphtheriae Crm19

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT